Retinitis Pigmentosa: Understanding Inherited Vision Loss

RP follows several different inheritance patterns, each with different implications for family members.

• Autosomal dominant RP: Only one copy of the mutated gene is needed to cause the disease. A child of an affected parent has roughly a 50 percent chance of inheriting it.
• Autosomal recessive RP: Both copies of a gene must be mutated. Both parents must each carry one faulty copy, and each child then has about a 25 percent chance of being affected.
• X-linked RP: This pattern primarily affects males. Females who carry the mutation often have mild symptoms or none at all, but they can pass it to their children.
• Sporadic RP: Some cases occur with no known family history, often due to a new mutation that was not inherited from either parent.

Genetic counseling can help clarify which pattern applies in your family and what it means for other relatives.

Having a parent, sibling, or other close relative diagnosed with RP is the strongest risk factor for developing the condition yourself. When parents are blood relatives, the risk for autosomal recessive forms of RP increases, because both parents are more likely to carry the same recessive mutation. If RP runs in your family, speaking with a retina specialist about screening and genetic testing is a meaningful step toward early detection.

In some cases, RP occurs alongside conditions that affect other parts of the body. Usher syndrome is the most common example, combining RP-related vision loss with hearing loss. Bardet-Biedl syndrome is another syndromic form that may involve RP along with features such as obesity and kidney problems. Genetic testing can identify whether RP is isolated or part of a broader syndrome, which can guide the overall care plan.

Luxturna (voretigene neparvovec) is the first FDA-approved gene therapy for an inherited retinal disease. It is designed specifically for patients whose RP or related condition is caused by mutations in both copies of the RPE65 gene. The therapy involves a surgical procedure that delivers a working copy of the RPE65 gene directly into the retina. Clinical studies have shown that this treatment can meaningfully improve the ability to see and navigate in low-light conditions.

It is important to understand that Luxturna treats only the RPE65 form of RP, which represents a small percentage of all cases. Genetic testing is required to determine whether this therapy is an option for a specific patient.

Some research has suggested that vitamin A palmitate may help slow retinal deterioration in certain patients with RP. However, high doses of vitamin A can be harmful, particularly to the liver, and are not appropriate for everyone. Pregnant women and those planning pregnancy should not take high-dose vitamin A supplements. Any use of vitamin A supplementation should be discussed with and supervised by a retina specialist or physician before starting.

People with RP are at increased risk for certain additional eye conditions that can further reduce vision. Cataracts (clouding of the eye's natural lens) are common and can be treated with surgery when they interfere with function. Cystoid macular edema, which is swelling in the central retina, can also occur and may be managed with medications such as carbonic anhydrase inhibitors. Identifying and treating these complications early can make a real difference in preserving functional vision.

Low vision rehabilitation helps people with RP make the most of their remaining vision. A wide range of tools and strategies can support daily life, including magnifying lenses, high-contrast screens, text-to-speech software, and adaptive lighting. Orientation and mobility training teaches individuals to move safely through their environment as vision changes. Our team can connect patients with low vision specialists and rehabilitation services tailored to their specific needs.

Yes, in many cases. Electroretinography can detect reduced electrical activity in the retina before noticeable vision changes occur. Genetic testing can also identify a mutation in at-risk family members who have not yet developed symptoms. For someone with a known family history of RP, proactive testing and establishing a baseline early gives our team the best foundation for monitoring changes over time and connecting the patient with emerging treatment options promptly.

Not at this time. The only FDA-approved gene therapy for inherited retinal disease, Luxturna, treats only the specific form of RP caused by mutations in both copies of the RPE65 gene. This affects a small percentage of all RP patients. Other gene therapies targeting different mutations are being studied in clinical trials but have not yet received approval. Genetic testing is the essential first step to determine whether any current or upcoming therapy may apply to your specific situation.

The answer depends on the inheritance pattern and the specific mutation involved. In autosomal dominant RP, each child of an affected parent has roughly a one-in-two chance of inheriting the condition. In autosomal recessive RP, when both parents carry the mutation, each child has about a one-in-four chance of being affected. In X-linked RP, a carrier mother has about a one-in-two chance of passing the mutation to each son. A genetic counselor can walk through the specific probabilities based on your family's confirmed test results and help you make informed decisions about family planning.

No lifestyle change has been proven to halt RP progression. That said, protecting the eyes from excessive sunlight with UV-blocking lenses, avoiding smoking, eating a diet that includes leafy greens and omega-3 fatty acids, and maintaining good general health are broadly supportive habits. Some retina specialists may discuss vitamin A supplementation with select patients, but this requires careful medical supervision due to real risks at high doses and is not appropriate for everyone, particularly women who are pregnant or may become pregnant.

The most important step is to schedule a comprehensive evaluation with a retina specialist, including electroretinography and a discussion about genetic testing. Having no symptoms does not mean the retina is unaffected, since ERG can detect changes before vision loss is noticeable. Establishing a baseline now allows our team to detect any future changes early and ensure you are considered for clinical trials or new therapies if they become relevant to your mutation. If you are also planning to start or grow a family, genetic counseling can provide personalized risk guidance.

For the diagnosis and ongoing management of RP, care from a retina specialist is strongly recommended. A retina specialist has the advanced training, equipment, and expertise needed to perform ERG, interpret OCT imaging, coordinate genetic testing, and stay current on emerging therapies. While a general eye doctor can play a supportive role, the complexity of RP warrants specialist-level oversight, particularly as new treatment options continue to develop. If you have been evaluated by a general eye doctor and RP is suspected, ask for a referral to a retina specialist as soon as possible.